Acquisition - May 4, 2026
UCB to acquire Candid Therapeutics
Belgian company UCB has announced signing of a definitive agreement under which it would acquire Candid Therapeutics, a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs).
Financing - April 28, 2026
Ray Therapeutics raises USD 125 million, Novo Holdings doubles down on optogenetic eye gene therapy
The US company has closed an upsized, oversubscribed Series B to advance its optogenetic gene therapy pipeline for blinding retinal diseases with Novo Holdings reinforcing a strong Nordic investment footprint in late‑stage ophthalmology.
Global report - April 24, 2026
Biogen in agreement with TJ Biopharma
The companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio’s exclusive rights to felzartamab in the Greater China Region.
Clinical Trials - April 15, 2026
Promising results about new Lyme disease vaccine candidate
Pfizer and Valneva's Lyme disease vaccine candidate demonstrated strong efficacy in their Phase 3 VALOR trial.
Global report - April 14, 2026
New investigation about Merck’s tactics to sustain high prices
A global investigation led by journalists from the International Consortium of Investigative Journalists shows how Merck & Co has deployed a range of strategies to sustain high prices and stifle competition.
Acquisition - April 7, 2026
MSD to acquire Terns Pharmaceuticals
MSD and Terns Pharmaceuticals have entered into a definitive agreement under which MSD, through a subsidiary, will acquire Terns for an approximate equity value of USD 6.7 billion.
